Harbour BioMed (“HBM”, HKEX: 02142) announced that it has successfully completed the dosing of first patient in phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in Australia. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of HBM7008 in patients with solid tumors. HBM7008 is generated from our unique and innovative HBICE® platform, leveraging the advantages of HBM HCAb and H2L2 platforms. It targets Tumor-Associated Antigen (B7H4), mediated crosslinking T cell activation through 4-1BB. B7H4...